Madrigal Pharmaceuticals, Inc. MDGL
We take great care to ensure that the data presented and summarized in this overview for MADRIGAL PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MDGL
View all-
Janus Henderson Group PLC London, X02.21MShares$737 Million0.36% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.04MShares$682 Million38.14% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$677 Million9.12% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$666 Million10.03% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$659 Million6.75% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.71MShares$570 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.43MShares$476 Million0.01% of portfolio
-
State Street Corp Boston, MA781KShares$261 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD589KShares$197 Million0.02% of portfolio
-
Geode Capital Management, LLC Boston, MA411KShares$137 Million0.01% of portfolio
Latest Institutional Activity in MDGL
Top Purchases
Top Sells
About MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Insider Transactions at MDGL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 13
2025
|
Fred B Craves Director |
SELL
Open market or private sale
|
Direct |
7,742
-0.27%
|
$2,523,892
$326.58 P/Share
|
|
Mar 13
2025
|
Fred B Craves Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,742
+2.12%
|
$503,230
$65.06 P/Share
|
|
Mar 12
2025
|
Fred B Craves Director |
SELL
Open market or private sale
|
Direct |
7,728
-0.44%
|
$2,565,696
$332.58 P/Share
|
|
Mar 12
2025
|
Fred B Craves Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,728
+1.07%
|
$680,064
$88.06 P/Share
|
|
Mar 10
2025
|
Mardi Dier SVP and CFO |
SELL
Open market or private sale
|
Direct |
258
-2.41%
|
$83,334
$323.04 P/Share
|
|
Mar 10
2025
|
Jacqualyn A Fouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
894
+50.0%
|
-
|
|
Mar 05
2025
|
William John Sibold President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
13,066
+10.02%
|
-
|
|
Mar 05
2025
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
2,061
+26.25%
|
-
|
|
Mar 05
2025
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
14,113
-14.66%
|
$4,798,420
$340.42 P/Share
|
|
Mar 05
2025
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
BUY
Exercise of conversion of derivative security
|
Direct |
14,113
+34.14%
|
$1,227,831
$87.5 P/Share
|
|
Mar 05
2025
|
Mardi Dier SVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
3,784
+26.13%
|
-
|
|
Mar 05
2025
|
Rebecca Taub Pres., R&D, and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
4,382
+0.94%
|
-
|
|
Mar 05
2025
|
Shannon T Kelley General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
3,187
+23.32%
|
-
|
|
Mar 05
2025
|
Carole Huntsman Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,386
+22.02%
|
-
|
|
Mar 03
2025
|
Shannon T Kelley General Counsel |
SELL
Open market or private sale
|
Direct |
415
-5.39%
|
$139,025
$335.0 P/Share
|
|
Mar 03
2025
|
Mardi Dier SVP and CFO |
SELL
Open market or private sale
|
Direct |
1,961
-11.72%
|
$635,364
$324.72 P/Share
|
|
Mar 03
2025
|
Carole Huntsman Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,834
-2.11%
|
$592,382
$323.86 P/Share
|
|
Feb 28
2025
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
1,227
-12.86%
|
$418,407
$341.27 P/Share
|
|
Feb 27
2025
|
William John Sibold President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+32.4%
|
-
|
|
Feb 27
2025
|
Kenneth Bate Director |
SELL
Open market or private sale
|
Direct |
20,000
-21.4%
|
$7,100,000
$355.92 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 42.4K shares |
|---|---|
| Exercise of conversion of derivative security | 404K shares |
| Open market or private sale | 380K shares |
|---|---|
| Bona fide gift | 99.9K shares |